Coralie Cantarel

Bordeaux, 33000, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Important aspects of care and priorities of older patients with cancer: The PRIORITY multicenter cohort study.

Important aspects of care and priorities of older patients with cancer: The PRIORITY multicenter cohort study.

Journal: Journal of geriatric oncology

Published: May 06, 2025

Important aspects of care and priorities of older patients with cancer: The PRIORITY multicenter cohort study.

Important aspects of care and priorities of older patients with cancer: The PRIORITY multicenter cohort study.

Journal: Journal of geriatric oncology

Published: May 06, 2025

Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab.

Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab.

Journal: Signal transduction and targeted therapy

Published: August 01, 2024

Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomics.

Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomics.

Journal: Molecular cancer

Published: July 19, 2024

Positive predictive value of malignancy for additional calcifications found during evaluation of a synchronous breast cancer.

Positive predictive value of malignancy for additional calcifications found during evaluation of a synchronous breast cancer.

Journal: European journal of radiology

Published: July 15, 2024

Regorafenib plus avelumab in advanced gastroenteropancreatic neuroendocrine neoplasms: a phase 2 trial and correlative analysis.

Regorafenib plus avelumab in advanced gastroenteropancreatic neuroendocrine neoplasms: a phase 2 trial and correlative analysis.

Journal: Nature cancer

Published: April 04, 2024

Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide.

Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide.

Journal: Molecular cancer

Published: January 15, 2024

Impact of the coronavirus disease 2019 pandemic on sarcoma management in France: a 2019 and 2020 comparison.

Impact of the coronavirus disease 2019 pandemic on sarcoma management in France: a 2019 and 2020 comparison.

Journal: Therapeutic advances in medical oncology

Published: May 03, 2023

Anastomotic leakage and functional outcomes following total mesorectal excision with delayed and immediate colo-anal anastomosis for rectal cancer: Two single-arm phase II trials.

Anastomotic leakage and functional outcomes following total mesorectal excision with delayed and immediate colo-anal anastomosis for rectal cancer: Two single-arm phase II trials.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: March 31, 2023

One-Year Follow-Up of Seroprevalence of SARS-CoV-2 Infection and Anxiety among Health Workers of a French Cancer Center: The PRO-SERO-COV Study.

One-Year Follow-Up of Seroprevalence of SARS-CoV-2 Infection and Anxiety among Health Workers of a French Cancer Center: The PRO-SERO-COV Study.

Journal: International journal of environmental research and public health

Published: March 29, 2023

Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer.

Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer.

Journal: Experimental hematology & oncology

Published: August 26, 2022

Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma.

Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma.

Journal: Journal of hematology & oncology

Published: July 28, 2022

Showing 1-12 of 17

Last Updated: 09/26/2026